Low temperature radiolabelling of human serum albumin constructs with terbium-161 and ex vivo biodistribution to assess in vivo stability

Research output: Contribution to report/book/conference proceedingsIn-proceedings paper

Authors

Institutes & Expert groups

  • KUL - Katholieke Universiteit Leuven

Documents & links

Abstract

Targeted radionuclide therapy using Terbium-161 (161Tb) is a promising approach for β- and Auger electron therapy. Heat-sensitive biomolecules (e.g. nanobodies) are increasingly being used as carriers in radiometal-based pharmaceuticals, however current radiolabelling techniques require heating (>85 °C) incompatible with heat-sensitive carrier molecules. In this study, we evaluated bifunctional chelators that allow 61Tblabelling under mild conditions using human serum albumin (HSA) and assessed the in vivo stability of the constructs.

Details

Original languageEnglish
Title of host publicationEuropean Journal of Nuclear Medicine and Molecular Imaging
PagesS753
Number of pages1
DOIs
Publication statusPublished - 30 Oct 2020
Event2020 - EANM: European Association of Nuclear Medicine - Online
Duration: 22 Oct 202030 Oct 2020
https://eanm20.eanm.org/

Publication series

NameEuropean Journal of Nuclear Medicine and Molecular Imaging
PublisherSpringer
NumberSupplement 1
Volume47
ISSN (Print)1619-7070

Conference

Conference2020 - EANM
Period2020-10-222020-10-30
Internet address

Keywords

  • Radiolabelling, Terbium-161, Biodistribution, In vivo stability

ID: 7070209